Ozempic compared to Trulicity led to: lower blood sugars based on HbA1c by about 0.3%(-1.4% vs -1.1%)
We often discuss incretin therapies in two phases: when to start them and when to stop them
In clinical trials, the most common side effect was headaches, occurring in 6% of users, followed by drooping eyelids in 2% of users, and facial asymmetry in 1% of users
The fairest one-line summary is that DSIP appears to have real biological activity but a weak and inconsistent clinical efficacy signal
This is often closely intertwined with mast cell activation syndrome (MCAS), where accumulated toxins and chronic oxidative stress cause mast cells to become hyper-reactive, constantly degranulating and releasing histamine and other inflammatory mediators into the bloodstream
In most cases, the body gradually adapts to treatment